Award

Oxidized LDL–Induced endothelial mitochondrial dysfunction as a driver of brain aging and cognitive impairment

Description: Dyslipidemia and aging are major risk factors for dementia, yet the mechanisms through which they interact to impair brain vessels remain poorly understood. The cerebral microcirculation is particularly vulnerable, as endothelial cells lining brain capillaries regulate blood flow, maintain the blood–brain barrier, and protect neurons. A growing body of evidence suggests that oxidized low-density lipoprotein (oxLDL), which increases with age and dyslipidemia, damages endothelial cell mitochondria, leading to oxidative stress, vascular dysfunction, and cognitive decline. Importantly, while statins and other lipid-lowering therapies reduce circulating cholesterol and have transformed cardiovascular care, they do not fully eliminate dementia risk. Many patients on optimal therapy still experience cerebrovascular complications, a residual risk driven in part by oxLDL-mediated oxidative stress, inflammation, and mitochondrial injury. Thus, therapies that specifically target oxLDL generation, clearance, or signaling are urgently needed to complement existing LDL-lowering strategies. The central hypothesis of this project is that dyslipidemia and aging synergistically impair brain microvascular function and cognition by inducing mitochondrial dysfunction and oxidative stress in endothelial cells. To test this, we will use LDL receptor knockout mice, a well-established genetic model of dyslipidemia, and aged wild-type controls. Aim 1 will determine how dyslipidemia and aging together impair brain blood vessel function and cognition. We will evaluate neurovascular coupling, cerebral blood flow, blood–brain barrier integrity, vascular density, and memory performance. We predict that aged dyslipidemic mice will show greater vascular and cognitive decline than aged controls. Aim 2 will test how oxLDL drives mitochondrial dysfunction and oxidative stress in brain endothelial cells. We will measure mitochondrial respiration, reactive oxygen species production, and endothelial barrier function in vivo and in vitro, and test whether treatment with the mitochondrial-targeted peptide SS-31 can restore endothelial function and protect cognition. This work is significant because it will define the causal role of oxLDL-mediated mitochondrial injury in age-related cerebrovascular decline. The expected outcomes are mechanistic insights into how aging and dyslipidemia interact to damage the brain and the identification of mitochondrial protection as a therapeutic strategy
Amount: $70,680
Funding type: training
Funder scheme: Predoctoral Fellowship
Start date: 2026-01-01
End date: 2027-12-31
Institutions: University of Oklahoma Health Sciences Center, Board of Regents of the University of Oklahoma, Health Sciences Center
Subfield: Neurology
Funded outputs count: 4
Funder award ID: 26PRE1560116
OpenAlex ID: G858617312